Literature DB >> 8327469

Thalidomide inhibits the replication of human immunodeficiency virus type 1.

S Makonkawkeyoon1, R N Limson-Pobre, A L Moreira, V Schauf, G Kaplan.   

Abstract

Thalidomide, a selective inhibitor of tumor necrosis factor alpha (TNF-alpha) synthesis, suppresses the activation of latent human immunodeficiency virus type 1 (HIV-1) in a monocytoid (U1) line. The inhibition is dose dependent and occurs after exposure of the cells to recombinant TNF-alpha, phorbol myristate acetate, lipopolysaccharide, and other cytokine combinations. Associated with HIV-1 inhibition is a reduction in agonist-induced TNF-alpha protein and mRNA production. Thalidomide inhibition of virus replication in the phorbol myristate acetate- and recombinant TNF-alpha-stimulated T-cell line ACH-2 is not observed. The presence of thalidomide also inhibits the activation of virus in the peripheral blood mononuclear cells of 16 out of 17 patients with advanced HIV-1 infection and AIDS. These results suggest the use of thalidomide in a clinical setting to inhibit both virus replication and the TNF-alpha-induced systemic toxicity of HIV-1 and opportunistic infections.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8327469      PMCID： PMC46849          DOI： 10.1073/pnas.90.13.5974

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  21 in total

1.  Long-term cultures of HTLV-III--infected T cells: a model of cytopathology of T-cell depletion in AIDS.

Authors:  D Zagury; J Bernard; R Leonard; R Cheynier; M Feldman; P S Sarin; R C Gallo
Journal:  Science       Date:  1986-02-21       Impact factor: 47.728

2.  Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV.

Authors:  T Folks; J Kelly; S Benn; A Kinter; J Justement; J Gold; R Redfield; K W Sell; A S Fauci
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

3.  Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate.

Authors:  T M Folks; J Justement; A Kinter; S Schnittman; J Orenstein; G Poli; A S Fauci
Journal:  J Immunol       Date:  1988-02-15       Impact factor: 5.422

4.  Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone.

Authors:  T M Folks; K A Clouse; J Justement; A Rabson; E Duh; J H Kehrl; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

5.  Productive human immunodeficiency virus-1 infection of megakaryocytic cells is enhanced by tumor necrosis factor-alpha.

Authors:  D Monté; H Groux; B Raharinivo; B Plouvier; J Dewulf; T Clavel; C Grangette; G Torpier; C Auriault; A Capron
Journal:  Blood       Date:  1992-05-15       Impact factor: 22.113

6.  Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone.

Authors:  K A Clouse; D Powell; I Washington; G Poli; K Strebel; W Farrar; P Barstad; J Kovacs; A S Fauci; T M Folks
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

7.  Shock and tissue injury induced by recombinant human cachectin.

Authors:  K J Tracey; B Beutler; S F Lowry; J Merryweather; S Wolpe; I W Milsark; R J Hariri; T J Fahey; A Zentella; J D Albert
Journal:  Science       Date:  1986-10-24       Impact factor: 47.728

Review 8.  The effect of cytokines and pharmacologic agents on chronic HIV infection.

Authors:  G Poli; A S Fauci
Journal:  AIDS Res Hum Retroviruses       Date:  1992-02       Impact factor: 2.205

9.  Rapid and sensitive viral culture method for human immunodeficiency virus type 1.

Authors:  J B Jackson; R W Coombs; K Sannerud; F S Rhame; H H Balfour
Journal:  J Clin Microbiol       Date:  1988-07       Impact factor: 5.948

10.  In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity.

Authors:  R L Willey; D H Smith; L A Lasky; T S Theodore; P L Earl; B Moss; D J Capon; M A Martin
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103
View more
  37 in total

1.  Idiopathic giant oesophageal ulcer in an immunocompetent patient. The efficacy of thalidomide treatment.

Authors:  S Ollivier; J Bonnet; M Lemann; J C Coffin; R Modigliani; R Jian; P Bertheau; J F Flejou
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

Review 2.  New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide.

Authors:  E Ravot; J Lisziewicz; F Lori
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 3.  Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs.

Authors:  Mayte Coiras; María Rosa López-Huertas; Mayte Pérez-Olmeda; José Alcamí
Journal:  Nat Rev Microbiol       Date:  2009-11       Impact factor: 60.633

4.  Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production.

Authors:  B E Turk; H Jiang; J O Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

5.  Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients.

Authors:  S C Piscitelli; W D Figg; B Hahn; G Kelly; S Thomas; R E Walker
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

Review 6.  Teratogenic effects of thalidomide: molecular mechanisms.

Authors:  Takumi Ito; Hideki Ando; Hiroshi Handa
Journal:  Cell Mol Life Sci       Date:  2011-01-05       Impact factor: 9.261

7.  Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor.

Authors:  Y Abu-Amer; F P Ross; J Edwards; S L Teitelbaum
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

8.  Inhibitory effects of thalidomide on cellular proliferation, endoneurial edema and myelin phagocytosis during early wallerian degeneration.

Authors:  J M Schröder; B Sellhaus; T Wöhrmann; B Kögel; K Zwingenberger
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

9.  Interleukin 1 induces HIV-1 expression in chronically infected U1 cells: blockade by interleukin 1 receptor antagonist and tumor necrosis factor binding protein type 1.

Authors:  E V Granowitz; B M Saget; M Z Wang; C A Dinarello; P R Skolnik
Journal:  Mol Med       Date:  1995-09       Impact factor: 6.354

10.  Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis.

Authors:  J M Tramontana; U Utaipat; A Molloy; P Akarasewi; M Burroughs; S Makonkawkeyoon; B Johnson; J D Klausner; W Rom; G Kaplan
Journal:  Mol Med       Date:  1995-05       Impact factor: 6.354
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.